Status | Study |
Recruiting |
Study Name: Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma Condition: Malignant Glioma Ependymoma Date: 2017-01-17 Interventions: Device: Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields) The Optune, a.k.a. Tumor Tr |
Recruiting |
Study Name: Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma Condition: Brain Tumor Recurrent Date: 2016-10-18 Interventions: Drug: 5-Azacytidine 5-Azacytidine 10 mg into the fourth ventricle of the brain via the Ommaya reservoir |
Recruiting |
Study Name: Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma Condition: Posterior Fossa Ependymoma (PFEPN) Date: 2016-05-06 Interventions: Drug: Trastuzumab after SubQ GM-CSF Drug: |
Recruiting |
Study Name: An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma Condition: Childhood Ependymoma Date: 2014-09-29 Interventions: Drug: 16 weeks of VEC + CDDP D |
Recruiting |
Study Name: Everolimus for Children With Recurrent or Progressive Ependymoma Condition: Recurrent Childhood Ependymoma Date: 2014-05-29 Interventions: Drug: Everolimus The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, unt |
Recruiting |
Study Name: A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma Condition: Ependymoma Date: 2014-04-25 Interventions: Radiation: Irradiation Radiati |
Recruiting |
Study Name: Immunotherapy for Recurrent Ependymomas in Children Treatment for Recurrent Ependymomas Using HLA-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod Condition: Ependymoma Date: 2013-02-12 Interventions: Biological: HLA-A2 restricted synthetic tumor antigen |
Completed |
Study Name: Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma Condition: Medulloblastoma, Childhood Cerebral Primitive Neuroectodermal Tumor Date: 2013-01-18 |
Completed |
Study Name: Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma Condition: Central Nervous System Malignancies Ependymoma Date: 2011-12-21 Interventions: Drug: 5-fluorouracil 5-fluorouracil, bolus dose of 500 mg/m^2 given weekly for 4 weeks followed by a two |
Completed |
Study Name: Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Condition: Childhood Cerebellar Anaplastic Astrocytoma Childhood Cerebral Anaplastic Astrocytoma Date: 2011-10-27 Interventions: Other: Diagnostic Laboratory Biomarker Analysis |